NCT05927857View on ClinicalTrials.gov

Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Metastatic Gastric AdenocarcinomaSecond LineChemotherapy
Interventions
DRUG

nal-IRI /Experimental

infusional 50/60/70 mg/m2 over 90 minutes day 1, every 14 days.

DRUG

Ramucirumab /Experimental

infusional 8mg/kg over 60 minutes day 1, every 14 days.

DRUG

Trifluridine/Tipiracil /Experimental

oral 30 mg/m2/b.i.d. day 1-5, every 14 days.

Trial Locations (1)

Unknown

RECRUITING

Taipei Veterans General Hospital, Taipei

All Listed Sponsors
collaborator

Taipei Veterans General Hospital, Taiwan

OTHER_GOV

collaborator

China Medical University Hospital

OTHER

collaborator

National Cheng-Kung University Hospital

OTHER

collaborator

Kaohsiung Medical University Chung-Ho Memorial Hospital

OTHER

collaborator

Chang Gung Memorial Hospital

OTHER

lead

National Health Research Institutes, Taiwan

OTHER